Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Steven Paul Balk, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Steven Balk and Joshua Russo.
Connection Strength

3.890
  1. Androgen Receptor Interaction with Mediator Complex Is Enhanced in Castration-Resistant Prostate Cancer by CDK7 Phosphorylation of MED1. Cancer Discov. 2019 11; 9(11):1490-1492.
    View in: PubMed
    Score: 0.842
  2. Initiation and Evolution of Early Onset Prostate Cancer. Cancer Cell. 2018 12 10; 34(6):874-876.
    View in: PubMed
    Score: 0.792
  3. Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res. 2018 11 15; 78(22):6354-6362.
    View in: PubMed
    Score: 0.780
  4. Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.240
  5. Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells. Cancer Lett. 2021 10 28; 519:172-184.
    View in: PubMed
    Score: 0.237
  6. Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett. 2018 12 01; 438:97-104.
    View in: PubMed
    Score: 0.195
  7. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018 08 15; 78(16):4716-4730.
    View in: PubMed
    Score: 0.191
  8. Positive feedback loop mediated by protein phosphatase 1a mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic Acids Res. 2017 04 20; 45(7):3738-3751.
    View in: PubMed
    Score: 0.177
  9. Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clin Cancer Res. 2017 Jul 15; 23(14):3823-3833.
    View in: PubMed
    Score: 0.174
  10. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med. 2021 03; 27(3):426-433.
    View in: PubMed
    Score: 0.058
  11. Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell Chem Biol. 2021 02 18; 28(2):134-147.e14.
    View in: PubMed
    Score: 0.056
  12. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. 2020 08 10; 38(2):279-296.e9.
    View in: PubMed
    Score: 0.055
  13. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest. 2019 01 02; 129(1):192-208.
    View in: PubMed
    Score: 0.049
  14. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clin Cancer Res. 2017 Nov 15; 23(22):6812-6822.
    View in: PubMed
    Score: 0.045
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.